ARHGEF34P: A Potential Drug Target and Biomarker (G728377)

Target Name: ARHGEF34P

NCBI ID: G728377

ARHGEF34P

Other Name(s): Rho guanine nucleotide exchange factor 34, pseudogene

ARHGEF34P: A Potential Drug Target and Biomarker

ARHGEF34P, also known as Rho guanine nucleotide exchange factor 34, is a protein that plays a crucial role in the regulation of protein synthesis in eukaryotic cells. It is a member of the Rho family of GTPases, which are known for their ability to transfer genetic information from the cell nucleus to the cytoplasm through the transfer of GTPases. ARHGEF34P is a pseudogene, which means that it encodes a protein that is similar to its functional counterpart in Escherichia coli but does not have the ability to catalyze GTPase activity.

Despite its non-catalytic function, ARHGEF34P is involved in the regulation of protein synthesis and has been implicated in a number of cellular processes, including cell growth, differentiation, and stress response. It is also a potential drug target and biomarker.

The Rho Family of GTPases

The Rho family of GTPases is a large and diverse group of proteins that play a critical role in cell signaling and regulation. They are characterized by the presence of a nucleotide-binding oligomerization domain (NBD), which is responsible for binding GTP to the nucleotide. This domain is typically followed by a catalytic domain that is responsible for the catalytic activity of the GTPase.

ARHGEF34P is a member of the Rho family of GTPases and is characterized by the presence of a NBD and a catalytic domain. It is similar to other members of the Rho family, such as RhoA, RhoB, and RhoC, in that it is involved in the regulation of protein synthesis and has been implicated in a number of cellular processes.

ARHGEF34P's Role in Protein Synthesis

ARHGEF34P is involved in the regulation of protein synthesis by interacting with the ribosome, which is the protein complex that is responsible for synthesizing new proteins from RNA. It does this by interacting with the A protein, which is a key component of the ribosome.

ARHGEF34P's interaction with A protein is critical for the regulation of protein synthesis, as it allows the cell to ensure that it has enough A protein to synthesize the necessary proteins. It does this by binding to the A protein and then interacting with the N-terminus of the protein, which is the region that is involved in the interaction with the ribosome.

In addition to its role in regulating protein synthesis, ARHGEF34P is also involved in the regulation of protein degradation. It does this by interacting with the protein degradation machinery, which is responsible for breaking down damaged or unnecessary proteins.

Potential Drug Target

ARHGEF34P is a potential drug target because of its involvement in the regulation of protein synthesis and cell signaling. Several studies have suggested that inhibiting the activity of ARHGEF34P may be a useful way to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One reason for thinking that ARHGEF34P may be a good drug target is that it is involved in a number of cellular processes that are important for the development and progression of these diseases. For example, ARHGEF34P is involved in the regulation of cell growth, which is a critical process for the development of cancer. It is also involved in the regulation of neurodegenerative diseases, such as Alzheimer's disease, which are characterized by the progressive loss of brain cells.

In addition to its involvement in these processes, ARHGEF34P is also thought to be involved in the regulation of autoimmune disorders, which are characterized by the activation and proliferation of the immune system.

Protein Name: Rho Guanine Nucleotide Exchange Factor 34, Pseudogene

The "ARHGEF34P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ARHGEF34P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets